Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome Kim CH; Younossi ZMCleve Clin J Med 2008[Oct]; 75 (10): 721-8Nonalcoholic fatty liver disease (NAFLD) has become the most common form of liver disease, affecting 20% to 30% of the US population. Its clinical manifestations are usually absent or subtle, and it usually comes to medical attention incidentally when aminotransferase levels are found to be elevated or a radiographic study reveals that the liver is fatty. Primary NAFLD is now considered the hepatic manifestation of the metabolic syndrome. The pathogenesis is thought to be a multiple-hit process involving insulin resistance, oxidative stress, apoptosis, and adipokines. In general, the prognosis for simple steatosis is very good; however, nonalcoholic steatohepatitis (NASH) can progress to cirrhosis and hepatocellular carcinoma in 10% to 15% of patients. There is no established treatment for NAFLD except for weight loss and treating each component of the metabolic syndrome.|Apoptosis[MESH]|Clinical Trials as Topic[MESH]|Diagnosis, Differential[MESH]|Disease Progression[MESH]|Fatty Liver/diagnosis/*etiology/prevention & control[MESH]|Humans[MESH]|Insulin Resistance[MESH]|Liver Cirrhosis/etiology[MESH]|Liver Function Tests[MESH]|Liver Neoplasms/etiology[MESH]|Metabolic Syndrome/*complications/therapy[MESH]|Oxidative Stress[MESH]|Prognosis[MESH]|Weight Loss[MESH] |
